<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00901017</url>
  </required_header>
  <id_info>
    <org_study_id>CR 04/05</org_study_id>
    <nct_id>NCT00901017</nct_id>
  </id_info>
  <brief_title>Comparison of Synthetic Bone Substitute and a Bovine-derived Xenograft in Horizontal Bone Augmentation</brief_title>
  <official_title>A Randomised Controlled Spilt-mouth Clinical Study Comparing a Synthetic Bone Substitute and a Bovine-derived Xenograft in Primarily Horizontal Bone Augmentation Procedure During Placement of Straumann Oral Implants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Straumann AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Straumann AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to test the efficacy on bone formation of Straumann Bone
      Ceramic as a grafting material applied in buccal bone dehiscences on simultaneously placed
      oral implants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled, split mouth, prospective, single centre study. The total
      study duration for each patient should be 76 weeks +/-18 months.

      In total 8 visits per patient are scheduled in this study.

      The study devices Straumann Bone Ceramic and Bio-Oss are CE-marked, and approved by the FDA.
      The products are used within the indication.

      One center in Beligum will participate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Vertical Height of Buccal Defects</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>Change of vertical height of buccal defects over 26 weeks, measured during 1st - and 2nd- stage surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implant Success Rate</measure>
    <time_frame>6 months</time_frame>
    <description>The success of oral implant will be determined according to the following parameters:
Absence of any continuous peri-implant radiolucency based on radiographic findings.
Absence of implant mobility (based on hand testing)
Absence of a peri-implant infection with suppuration.
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics).
Bone level changes evaluated on periapical radiographs around implants less than 1 mm during the first year of loading, starting at abutment connection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant Survival Rate</measure>
    <time_frame>6 Months</time_frame>
    <description>A surviving implant will be considered an implant fulfilling the following criteria:
Absence of any continuous peri-implant radiolucency based on radiographic findings.
Absence of implant mobility.
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics).
Absence of pain or any other adverse observation by the patient, so that the implant has to be removed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant Success Rate</measure>
    <time_frame>12 months</time_frame>
    <description>The success of oral implant will be determined according to the following parameters:
Absence of any continuous peri-implant radiolucency based on radiographic findings.
Absence of implant mobility (based on hand testing)
Absence of a peri-implant infection with suppuration.
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics).
Bone level changes evaluated on periapical radiographs around implants less than 1 mm during the first year of loading, starting at abutment connection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant Survival Rate</measure>
    <time_frame>12 months</time_frame>
    <description>A surviving implant will be considered an implant fulfilling the following criteria:
Absence of any continuous peri-implant radiolucency based on radiographic findings.
Absence of implant mobility.
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics).
Absence of pain or any other adverse observation by the patient, so that the implant has to be removed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Jaw, Edentulous</condition>
  <condition>Jaw, Edentulous, Partially</condition>
  <arm_group>
    <arm_group_label>Straumann BoneCeramic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Straumann BoneCeramic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bio-Oss</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Geistlich Bio-Oss</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Straumann BoneCeramic</intervention_name>
    <description>Bone augmentation procedure performed with Bone Ceramic</description>
    <arm_group_label>Straumann BoneCeramic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bio-Oss</intervention_name>
    <description>Bone Augmentation procedure performed with Bio Oss</description>
    <arm_group_label>Bio-Oss</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 18 years to 80 years of age

          -  At least two missing teeth up to full edentulous arches.

          -  Desiring implant supported restorations.

          -  Both study implants should have a self-containing (2-wall) buccal dehiscence defect
             after oral implant placement (at least 3.0 mm / max. 5.0 mm defect in apico-coronal
             aspect to be measured from the boarder of the rough surface of the oral implant to the
             bottom of the defect).

          -  At least 4mm of the implant, measured from the apical end to the lowest margin of the
             bone level, should be covered with bone.

          -  Sufficient bone volume such that both oral implants will not encroach on vital
             structures and primary stability of the oral implant can be achieved;

          -  Patients must be committed to the study and must sign informed consent.

          -  Patient in good general health as documented by self assessment;

          -  Full mouth plaque score of &lt;20%;

        Exclusion Criteria:

          -  Any systemic medical condition that could interfere with the surgical procedure or
             planned treatment;

          -  Current pregnancy or breast feeding/ lactating at the time of recruitment;

          -  Physical handicaps that would interfere with the ability to perform adequate oral
             hygiene;

          -  Alcoholism or chronically drug abuse causing systemic compromise.

          -  Patients who smoke more than 20 cigarettes per day.

          -  Conditions or circumstances, in the opinion of the investigator, which could represent
             a general contra-indication for surgical procedure or would prevent completion of
             study participation or interfere with analysis of study results, such as history of
             non-compliance, or unreliability

          -  Lack of primary stability of 1 or both implant(s) at surgery, measured by hand
             testing. In this instance the patient must be withdrawn and treated accordingly.

          -  Mucosal diseases such as erosive lichen planus

          -  History of local radiation therapy.

          -  Presence of osseous pathologies.

          -  Presence of oral lesions (such as ulceration, malignancy)

          -  Severe bruxing or clenching habits.

          -  Local inflammation, including untreated periodontitis.

          -  Bone surgery at the implant site(s) (bone grafts, guided tissue regeneration
             techniques for bone enhancement) prior to implant placement unless performed more than
             6 months prior to implant placement.

          -  Patients presenting clinical and radiological signs and symptoms of maxillary sinus
             disease.

          -  Existing teeth in the residual dentition with untreated endodontic pathologies.

          -  Patients with inadequate oral hygiene or unmotivated for adequate home care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Quirynen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Katholieke Universiteit Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Katholieke Universiteit Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <results_first_submitted>August 30, 2012</results_first_submitted>
  <results_first_submitted_qc>October 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 5, 2012</results_first_posted>
  <last_update_submitted>March 2, 2016</last_update_submitted>
  <last_update_submitted_qc>March 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth, Edentulous</mesh_term>
    <mesh_term>Jaw, Edentulous</mesh_term>
    <mesh_term>Jaw, Edentulous, Partially</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Straumann BoneCeramic and Geistlich Bio-Oss</title>
          <description>Each patient received both treatments in a split-mouth design.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Straumann BoneCeramic and Geistlich Bio-Oss</title>
          <description>Each patient received both treatments in a split-mouth design.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.1" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Vertical Height of Buccal Defects</title>
        <description>Change of vertical height of buccal defects over 26 weeks, measured during 1st - and 2nd- stage surgery</description>
        <time_frame>Baseline to 26 weeks</time_frame>
        <population>14 patients represented the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Straumann BoneCeramic</title>
            <description>In the test site the bone grafting procedure will be done with a synthetic biphasic calcium phosphate in particulate form (Straumann Bone Ceramic, Institute Straumann AG, Switzerland).</description>
          </group>
          <group group_id="O2">
            <title>Geistlich Bio-Oss</title>
            <description>The control site will be treated with a granular bone substitute derived from bovine bone (Bio-Oss - Geistlich Biomaterials, Wollhusen, Switzerland).</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Vertical Height of Buccal Defects</title>
          <description>Change of vertical height of buccal defects over 26 weeks, measured during 1st - and 2nd- stage surgery</description>
          <population>14 patients represented the ITT population.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" lower_limit="-5.8" upper_limit="-3.2"/>
                    <measurement group_id="O2" value="-4.82" lower_limit="-5.9" upper_limit="-3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implant Success Rate</title>
        <description>The success of oral implant will be determined according to the following parameters:
Absence of any continuous peri-implant radiolucency based on radiographic findings.
Absence of implant mobility (based on hand testing)
Absence of a peri-implant infection with suppuration.
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics).
Bone level changes evaluated on periapical radiographs around implants less than 1 mm during the first year of loading, starting at abutment connection.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Straumann BoneCeramic</title>
            <description>In the test site the bone grafting procedure will be done with a synthetic biphasic calcium phosphate in particulate form (Straumann Bone Ceramic, Institute Straumann AG, Switzerland).</description>
          </group>
          <group group_id="O2">
            <title>Geistlich Bio-Oss</title>
            <description>The control site will be treated with a granular bone substitute derived from bovine bone (Bio-Oss - Geistlich Biomaterials, Wollhusen, Switzerland)</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Success Rate</title>
          <description>The success of oral implant will be determined according to the following parameters:
Absence of any continuous peri-implant radiolucency based on radiographic findings.
Absence of implant mobility (based on hand testing)
Absence of a peri-implant infection with suppuration.
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics).
Bone level changes evaluated on periapical radiographs around implants less than 1 mm during the first year of loading, starting at abutment connection.</description>
          <units>% of implants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implant Survival Rate</title>
        <description>A surviving implant will be considered an implant fulfilling the following criteria:
Absence of any continuous peri-implant radiolucency based on radiographic findings.
Absence of implant mobility.
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics).
Absence of pain or any other adverse observation by the patient, so that the implant has to be removed.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Straumann BoneCeramic</title>
            <description>In the test site the bone grafting procedure will be done with a synthetic biphasic calcium phosphate in particulate form (Straumann Bone Ceramic, Institute Straumann AG, Switzerland).</description>
          </group>
          <group group_id="O2">
            <title>Geistlich Bio-Oss</title>
            <description>The control site will be treated with a granular bone substitute derived from bovine bone (Bio-Oss - Geistlich Biomaterials, Wollhusen, Switzerland)</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Survival Rate</title>
          <description>A surviving implant will be considered an implant fulfilling the following criteria:
Absence of any continuous peri-implant radiolucency based on radiographic findings.
Absence of implant mobility.
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics).
Absence of pain or any other adverse observation by the patient, so that the implant has to be removed.</description>
          <units>% of implants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implant Success Rate</title>
        <description>The success of oral implant will be determined according to the following parameters:
Absence of any continuous peri-implant radiolucency based on radiographic findings.
Absence of implant mobility (based on hand testing)
Absence of a peri-implant infection with suppuration.
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics).
Bone level changes evaluated on periapical radiographs around implants less than 1 mm during the first year of loading, starting at abutment connection.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Straumann BoneCeramic</title>
            <description>In the test site the bone grafting procedure will be done with a synthetic biphasic calcium phosphate in particulate form (Straumann Bone Ceramic, Institute Straumann AG, Switzerland).</description>
          </group>
          <group group_id="O2">
            <title>Geistlich Bio-Oss</title>
            <description>The control site will be treated with a granular bone substitute derived from bovine bone (Bio-Oss - Geistlich Biomaterials, Wollhusen, Switzerland)</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Success Rate</title>
          <description>The success of oral implant will be determined according to the following parameters:
Absence of any continuous peri-implant radiolucency based on radiographic findings.
Absence of implant mobility (based on hand testing)
Absence of a peri-implant infection with suppuration.
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics).
Bone level changes evaluated on periapical radiographs around implants less than 1 mm during the first year of loading, starting at abutment connection.</description>
          <units>% of implants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implant Survival Rate</title>
        <description>A surviving implant will be considered an implant fulfilling the following criteria:
Absence of any continuous peri-implant radiolucency based on radiographic findings.
Absence of implant mobility.
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics).
Absence of pain or any other adverse observation by the patient, so that the implant has to be removed.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Straumann BoneCeramic</title>
            <description>In the test site the bone grafting procedure will be done with a synthetic biphasic calcium phosphate in particulate form (Straumann Bone Ceramic, Institute Straumann AG, Switzerland).</description>
          </group>
          <group group_id="O2">
            <title>Geistlich Bio-Oss</title>
            <description>The control site will be treated with a granular bone substitute derived from bovine bone (Bio-Oss - Geistlich Biomaterials, Wollhusen, Switzerland)</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Survival Rate</title>
          <description>A surviving implant will be considered an implant fulfilling the following criteria:
Absence of any continuous peri-implant radiolucency based on radiographic findings.
Absence of implant mobility.
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics).
Absence of pain or any other adverse observation by the patient, so that the implant has to be removed.</description>
          <units>% of implants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Straumann BoneCeramic</title>
          <description>In the test site the bone grafting procedure will be done with a synthetic biphasic calcium phosphate in particulate form (Straumann Bone Ceramic, Institute Straumann AG, Switzerland).</description>
        </group>
        <group group_id="E2">
          <title>Geistlich Bio-Oss</title>
          <description>The control site will be treated with a granular bone substitute derived from bovine bone (Bio-Oss - Geistlich Biomaterials, Wollhusen, Switzerland).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Membrane necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Candida</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marc Quirynen, Professor</name_or_title>
      <organization>Institut Straumann AG</organization>
      <phone>+4161965 ext 1235</phone>
      <email>michael.hotze@straumann.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

